Sanofi S.A. (SAN.PAR) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates the moment the expiry date moves. Positive Q4 four-weekly dosing data in 2028-2029, combined with formulation patents pushing effective exclusivity toward 2033 [8], converts Dupixent from a depreciating asset into a durable annuity. That alone justifies a mid-teens multiple, and it would arrive alongside duvakitug validation and a disciplined acquisition. Compounding earnings then meet an expanding multiple, the classic double engine, lifting the shares well above EUR 110.

The bear case needs two failures to coincide. Dupixent growth decelerates earlier than modelled as oral competitors and the unresolved Regeneron dispute bite, while the January 2029 MFN shelter lapses into punitive Section 232 duties [19]. Margin leverage then runs in reverse against a fixed cost base, management responds with an expensive, debt-funded acquisition, and the multiple compresses below 8x. Dividend cover tightens, and the shares revisit the low sixties.

The settled belief is that Sanofi is a one-molecule company with an expiry date stamped on it. Sell-side treats Dupixent's March 2031 US compound patent as a countdown clock [8], and July's cancellation of amlitelimab, itepekimab and balinatunfib hardened that conviction into fact [1][7]. The anchoring bias: a single-digit business-earnings multiple that prices post-2031 cash flow at close to nothing.

The crowd underestimates these shares, though modestly rather than dramatically. The decisive blind spot is measurement: trailing IFRS earnings embed a EUR 2,693m Opella gain in 2025 and a EUR 1,031m impairment in 2026 [1][3], so the widely quoted 12.9x trailing multiple is fiction. On business EPS tracking near EUR 7.9, the stock trades around 9.4x with a mid-5% yield. The market correctly identifies the 2031 problem but is discounting five years of intervening compounding almost entirely.

The capital markets day updating the 2030 ambition under Garijo and Fontoura [15] is the trigger. A credible replacement roadmap plus Q4-dosing trial progress would force analysts to extend the terminal date. Expect the first sign as multiple expansion from roughly 9x toward 11x business earnings, likely during 2027-2028.